BIORA THERAPEUTICS, INC.
bioratherapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 14, 2024. Its latest SEC filing is a SCHEDULE 13G/A from Aug 4, 2025.
10-Q for Q3 FY2024, filed Nov 14, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops ingestible drug-delivery platforms for patients with inflammatory bowel disease and other chronic conditions, including targeted gastrointestinal delivery and needle-free oral delivery of large-molecule medicines.
10-K for FY2023, filed Apr 1, 2024Biora Therapeutics, Inc. is a clinical-stage biotechnology company developing oral biotherapeutics that could enable new treatment…View ↗
NaviCapTM Targeted Oral Delivery Platform: Delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract designed to…View ↗
BioJetTM Systemic Oral Delivery Platform: Designed to replace injection with needle-free, oral delivery of large molecules for better…View ↗
How Did They Make Money?
Current revenue is related to license and collaboration agreements. Historically, healthcare insurers, government payors, laboratory partners and patients paid for molecular tests, with billing when test results were delivered.
10-K for FY2023, filed Apr 1, 2024
$4K
-
10-K for FY2023, filed Apr 1, 2024
$4K ↗
Who Were Their Customers?
Historically, physicians ordered molecular tests for patients; payment came through health insurers, government payors, laboratory distribution partners and patients. For its therapeutic platforms, the company seeks pharmaceutical collaborators.
10-K for FY2020, filed Mar 18, 2021 10-K for FY2023, filed Apr 1, 2024Our commercial team of more than 150 individuals actively engages with physicians and their staff to emphasize the clinical need for our…View ↗
Did Revenues Turn Into Profits?
No. It lost $124.1M in FY2023.
10-K for FY2023, filed Apr 1, 2024
−$67.1MView ↗
10-K for FY2023, filed Apr 1, 2024
−$124.1MView ↗
10-K for FY2023, filed Apr 1, 2024
−$48.6MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2024, filed Nov 14, 2024
−$18.4MView ↗
- ▼ −75% (Loss)
- vs −$73.5M in Q3 FY2023
-
Dec 30, 2024
Filed for Chapter 11 and began a court-supervised sale process
The company said it would continue operating while seeking a sale of its business or assets.
Sources
8-K, filed Dec 30, 2024
On December 27, 2024, Biora Therapeutics, Inc. (the “Company” or the “Debtor”) filed a voluntary petition (the “Chapter 11 Case”) for…View ↗
-
Dec 10, 2024
Nasdaq decided to delist the company's securities
The company said trading would be suspended and its shares would move to the OTC Pink Current Information tier.
Sources
8-K, filed Dec 10, 2024
Biora Therapeutics, Inc. (the “Company”) today announced that on December 9, 2024, the Company received formal notice from The Nasdaq Stock…View ↗
Shrank. Revenue fell 100% in 4 years, from $144M in FY2019 to $4K in FY2023, about 93% a year.
From molecular testing to therapeutic delivery
The earlier report presents commercial molecular testing and pathology as core businesses alongside investigational GI products; the latest centers on clinical-stage oral therapeutic delivery, with laboratory operations discontinued.
10-K for FY2020, filed Mar 18, 2021 10-K for FY2023, filed Apr 1, 2024We are a biotechnology company with an established track record of success in developing and commercializing molecular testing products as…View ↗
In 2015, we launched both our Innatal Prenatal Screen, a Non-Invasive Prenatal Testing, or NIPT, offering, and our Preparent Carrier Test…View ↗
We believe our future success will be driven by continued capture of market share by our molecular testing business and new revenue streams…View ↗
Biora Therapeutics, Inc. is a clinical-stage biotechnology company developing oral biotherapeutics that could enable new treatment…View ↗
Our historical operations included a licensed Clinical License Improvement Amendment ("CLIA") and College of American Pathologists ("CAP")…View ↗
In June 2021, we announced a strategic transformation ("Strategic Transformation") that included the closure of our genetics lab in Ann…View ↗
Preeclampsia test licensing
The earlier report describes the Preecludia test as in development; the latest says the company licensed it for commercial development in exchange for milestone payments and royalties.
10-K for FY2020, filed Mar 18, 2021 10-K for FY2023, filed Apr 1, 2024We are developing a rule-out test for preeclampsia, branded as Preecludia™. Based on our estimates, annually, over 700,000 pregnant women…View ↗
We had historically been developing a rule-out test for preeclampsia, branded as the Preecludia™ test, as part of our discontinued…View ↗
Who Did They Compete With?
Competes with AbbVie, Eli Lilly, Galapagos, Gilead, Pfizer, Protagonist, Roche, Takeda, UCB, Enteris Biopharma, Novo Nordisk, Catalent, Cosmo Pharmaceuticals, Intract Pharma, Lonza, Tillotts Pharma, Lyndra Therapeutics, Rani Therapeutics, Biograil, and Amgen
10-K for FY2023, filed Apr 1, 2024The current IBD market is both established and mature, comprised of a range of therapeutic agents, including branded and generic small…View ↗
Loading...
